← Back to all trials
Completed
NCT07233096
Rectus-Intercostal Fascial Plane Block for Liver Transplantation Donors
Conditions: Liver Transplantation, Living Donor, Postoperative Pain
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: NA
Enrollment: 64
Sponsor: Istinye University
Location: istinye University Istanbul
Summary
Postoperative pain control plays a crucial role in enhancing recovery and improving early mobilization in living liver donors. The rectus-intercostal fascial plane (RIFP) block is a novel ultrasound-guided regional anesthesia technique that provides anterior abdominal wall analgesia by targeting the intercostal nerves between the rectus abdominis and intercostal muscle fascia.
This prospective, randomized controlled clinical study aims to evaluate the postoperative analgesic efficacy and opioid-sparing effects of the RIFP block compared with standard intravenous analgesia in living liver donors undergoing donor hepatectomy.
Participants will be randomly assigned to two groups:
Group 1 (RIFP Block): Patients receiving an ultrasound-guided rectus-intercostal fascial plane block using 20 mL of 0.25% bupivacaine at the end of surgery, in addition to standard IV PCA (morphine).
Group 2 (Control): Patients receiving only standard IV PCA (morphine) without regional block.
Eligibility Criteria
Inclusion Criteria:
* Age between 18 and 75 years
* Patients with American Society of Anesthesiology (ASA) physical status I-II
* Patients scheduled for a living donor hepatectomy
Exclusion Criteria:
* Allergy to local anesthetics
* Coagulopathy
* Skin infection at the block area
* Advanced renal failure
* Chronic pain syndromes
* Alcohol or drug abuse
* Psychiatric disorders
Source: ClinicalTrials.gov (NCT07233096). StuddyBuddy aggregates publicly available trial information.